300
Views
2
CrossRef citations to date
0
Altmetric
Original Article: Clinical

An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial

, , , , , , , , , , , , , , , & show all
Pages 630-638 | Received 02 Mar 2014, Accepted 12 May 2014, Published online: 04 Aug 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

He Li, Wanhua Zhang, Dongni Yi, Yuanxin Ye & Xueqiu Xiao. (2017) Screening ABL1 kinase domain mutations in patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Leukemia & Lymphoma 58:4, pages 1005-1007.
Read now

Articles from other publishers (1)

Giovanni MartinelliCristina Papayannidis, Alfonso Piciocchi, Valentina Robustelli, Simona Soverini, Carolina Terragna, Giovanni Marconi, Roberto M. LemoliFabio Guolo, Antonella FornaroMonia LunghiPaolo de FabritiisAnna CandoniCarmine SelleriFederico SimonettiMonica Bocchia, Antonella VitaleLuca Frison, Alessandra TedeschiAntonio Cuneo, Massimiliano Bonifacio, Maria Paola Martelli, Stefano D’ArdiaSilvia TrappoliniPatrizia TosiPiero GalieniFrancesco FabbianoMaria Chiara AbbenanteMuriel Granier, Zhaoyin Zhu, Mingyue Wang, Chiara SartorStefania PaoliniMichele CavoRobin FoàPaola FaziMarco Vignetti & Michele Baccarani. (2022) INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Advances 6:6, pages 1742-1753.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.